Modelling the dynamics of Anti-HBV Infection Therapy with Chinese Herbs

被引:0
|
作者
Ye, Yongan [1 ]
Min, Lequan [2 ]
机构
[1] Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing 100700, Peoples R China
[2] Univ Sci & Technol Beijing, Appl Sci Sch, Beijing 100083, Peoples R China
关键词
hepatitis B; Chinese Herbs; anti-HBV infection therapy model; CHRONIC HEPATITIS-B; VIRUS-INFECTION; COMBINATION; LAMIVUDINE;
D O I
暂无
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Effective treatment of chronic Hepatitis B virus (HBV) patients aims to prevent progression of chronic hepatitis B to cirrhosis, hepatocellular carcinoma, and eventually death. The use of mathematical modelling to explain the anti-HBV infection therapy has made a significant contribution for understanding the dynamics of host cells, viruses, the immune system. Chinese herbs are playing important roles for anti-HBV infection treatment. Recently a new type of Chinese herbs (NTCH) has been proved to be effective for anti-HBV infection therapy. Based on a patient's anti-hepatitis B virus (HBV) infection therapy clinical data with the NTCH and our previous modified basic virus infection model [1], a new differential equation model with an immune variable is set up. The numerical simulations of the model show that the evolution of the HBV DNA of the model is agreement with in the patient's clinic plasma HBV DNA levels. The model predicts that it needs to prolong the treatment time to 4.3 years to eliminate NTCH the HBV virus in the patient's infected hepatocytes. Otherwise earlier cessation of the therapy will make the patient's HBV DNA levels return rapidly.
引用
收藏
页码:83 / +
页数:2
相关论文
共 50 条
  • [31] Comprehensive investigation of HBV-related hepatocellular carcinoma and choice of anti-HBV therapy
    Huihui Lu
    Wei Yi
    Fangfang Sun
    Zhan Zeng
    Lu Zhang
    Minghui Li
    Yao Xie
    生物安全与健康(英文), 2021, 03 (04) : 190 - 196
  • [32] DAPD - Anti-HIV - Anti-HBV
    不详
    DRUGS OF THE FUTURE, 2001, 26 (05) : 499 - 500
  • [33] DAPD -: Anti-HIV anti-HBV
    Furman, PA
    Cleary, D
    Trost, LC
    Bigley, JW
    Painter, GR
    DRUGS OF THE FUTURE, 2000, 25 (05) : 454 - 461
  • [34] Pharmacokinetics of Anti-HBV Polyoxometalate in Rats
    Wang, Juan
    Qu, Xiaofeng
    Qi, Yanfei
    Li, Jinhua
    Song, Xiuling
    Li, Li
    Yin, Dehui
    Xu, Kun
    Li, Juan
    PLOS ONE, 2014, 9 (06):
  • [35] Oncostatin M for Anti-HBV Therapy: Can a Foe Be Turned Into a Friend?
    Cheng, Tao
    Cheng, Yun
    Jin, Dong-Yan
    CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 2024, 17 (02): : 309 - 310
  • [36] Prophylactic anti-HBV therapy in hematopoietic stem-cell transplantation
    Nature Clinical Practice Gastroenterology & Hepatology, 2005, 2 (8): : 340 - 341
  • [37] A controlled study of anti-HBV vaccine therapy in HBsAg healthy carriers
    Pol, S
    Chaix, M
    Nalpas, B
    Tiollais, P
    Michel, M
    Brechot, C
    JOURNAL OF HEPATOLOGY, 2001, 34 : 196 - 197
  • [38] ANTI-HBV CONSTITUENTS OF MEDICINAL PLANTS
    Chen, G. Y.
    Liu, M.
    Jiang, Z. G.
    Yu, M. B.
    Wei, S. C.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 119 : 27 - 27
  • [39] Current status of anti-HBV chemotherapy
    Joon H. Hong
    Yongseok Choi
    Byoung K. Chun
    Kyeong Lee
    Chung K. Chu
    Archives of Pharmacal Research, 1998, 21 : 89 - 105
  • [40] Current status of anti-HBV chemotherapy
    Hong, JH
    Choi, YS
    Chun, BK
    Lee, K
    Chu, CK
    ARCHIVES OF PHARMACAL RESEARCH, 1998, 21 (02) : 89 - 105